🇺🇸 FDA
Patent

US 12428480

Anti-CD19 antibodies and multi-specific binding proteins

granted A61KA61K2039/505A61P

Quick answer

US patent 12428480 (Anti-CD19 antibodies and multi-specific binding proteins) held by Cullinan Therapeutics, Inc. expires Mon Sep 25 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Cullinan Therapeutics, Inc.
Grant date
Tue Sep 30 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 25 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
11
CPC classes
A61K, A61K2039/505, A61P, A61P31/04, A61P35/00